Effects of xuezhikang and simvastatin on cerebral ischemia-reperfusion injury in rat.
- Author:
Fu-You ZHOU
1
;
Jin ZHANG
;
Tao SONG
;
Feng GAO
;
Ji-Min WU
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Brain; pathology; Brain Ischemia; etiology; metabolism; pathology; Drugs, Chinese Herbal; pharmacology; Infarction, Middle Cerebral Artery; complications; Male; Malondialdehyde; metabolism; NG-Nitroarginine Methyl Ester; pharmacology; Neuroprotective Agents; pharmacology; Rats; Rats, Sprague-Dawley; Reperfusion Injury; etiology; metabolism; pathology; Simvastatin; pharmacology
- From: China Journal of Chinese Materia Medica 2006;31(17):1447-1450
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the effects of Xuezhikang and simvastatin on cerebral ischemia/reperfusion injury in rat, as well as the influences after intervention with L-NAME.
METHODRats were given orally with Xuezhikang and simvastatin or vehicle for 2 weeks, and then subjected to middle cerebral artery occlusion for 120 min using intraluminal filament model. L-NAME were injected into the lateral ventricles in half of the rats treated with Xuezhikang and simvastatin 45 min before the ischemia. The neurological deficits examinations were performed at 2, 24, 48 h after reperfusion. After the last examination the animals were sacrificed, the infarct volumes were determined by TTC staining, and MDA levels were also measured.
RESULTXuezhikang and simvastatin both significantly reduced the infarct volume and improved the functional recovery when compared to vehicle. Xuezhikang and simvastatin both significantly decreased the MDA accumulation after reperfusion. L-NAME partially inhibited the protective effect of Xuezhikang but nearly completely abolished the protective effect of simvastatin.
CONCLUSIONXuezhikang has protective effects on ischemic brain damage in rats, which the beneficial effects are partly due to the statins components. The other components in Xuezhikang may also account for the neuroprotective effects, which is worth further investigations.